Expression of lymphoid enhancing factor-1 in multiple myeloma and its clinical significance

Abstract

Objective To investigate the mRNA level of lymphoid enhancing factor-1 (LEF-1) in bone marrow mononuclear cells after the initial diagnosis and chemotherapy of patients with multiple myeloma (MM) and its clinical significance. Methods The LEF-1 mRNA of target gene in 42 MM patient was detected by real-time fluorescence quantitative polymerase chain reaction (RTQ-PCR), and 20 patients without hematological disease were enrolled as the healthy controls. Results The LEF-1 mRNA median level in previously diagnosed MM patients was significantly higher than that in the healthy controls [0.010 68 (0.000 17- 0.141 00) vs. 0.001 01 (0.000 09- 0.002 326)], and the difference was statistically significant (U= 91.00, P < 0.001); The LEF-1 mRNA median level in MM patients after chemotherapy was declined compared with the patients before chemotherapy [0.000 11 (0.000 01- 0.015 48) vs. 0.010 68 (0.000 17- 0.141 00)], and the difference was statistically significant (U= 343.0, P < 0.001). The LEF-1 mRNA median level of MM patients after chemotherapy in progression of disease (PD) group was higher than that in the non-PD groups [0.083 86 (0.002 88- 0.141 00) vs. 0.003 454 (0.000 156- 0.056 60)], and the difference was statistically significant (U= 343.0, P < 0.001). The overall survival (OS) rate in the high LEF-1 expression group was shorter than that in the low LEF-1 expression group for MM patients in the initial diagnosis (47.6% vs. 65.5%, χ2= 3.931, P= 0.041 4). Conclusion LEF-1 may be involved in the occurrence and development of MM, which has a potential to become an indicator of evaluating the poor prognosis and PD of MM patients, and could be served as a novel therapy target for the treatment of MM. Key words: Multiple myeloma; Lymphoid enhancing factor-1; Polymerase chain reaction; Prognosis; Target